Business Wire

CA-SYNACK

6.6.2019 17:02:17 CEST | Business Wire | Press release

Share
Crowdsourced Security Testing that Puts Privacy First

Today, Synack, the most trusted crowdsourced security testing platform and top choice of major enterprises and governments, becomes the only crowdsourced penetration testing company to offer secure and managed workspaces with endpoint control. LaunchPoint+ extends Synack’s original LaunchPoint VPN offering by providing a managed workspace environment for crowdsourced testing of enterprise and government assets.

In the midst of calls for greater consumer privacy from the European Commission to Apple, and states like NY and CA introducing bold privacy bills, Synack is launching their new LaunchPoint+ product to help organizations meet today’s rising security standards. Just as Apple now provides privacy-as-a-service (PaaS) to accommodate consumer privacy demands in their latest iOS upgrade, Synack is providing additional privacy and data control to its customers.

As GDPR, HIPAA, PCI-DSS and ISO 27001 require increasingly stringent requirements for data privacy, Synack has developed a new offering to help meet, and in some cases exceed, what is required. In use cases that require extra care (such as where PII data is involved), consumers and regulators alike are increasingly demanding more attention for data privacy. A violation of GDPR could result in a fine of up to 4% of annual revenue, incentivizing organizations to protect the data in their care.

Many organizations, both governments and enterprises, are held to regulatory standards that demand heightened requirements around privacy. For others such as Apple, enforcement of privacy is a way to develop more trust with their customers and differentiate their brands. In a recent survey by SAS, 73% of consumers said their concerns over data privacy were increasing. Synack has responded by providing managed workspaces with endpoint controls to give these organizations the data protection and privacy environment during the testing period that they need.

As the leader of crowdsourced security, Synack has continuously brought to market new technology features that build, measure, and demonstrate trust between enterprises and their customers, and organizations and ethical hackers. Through innovations like the Attacker Resistance Score, Coverage Analytics, Trust Report, and Guardians of Trust Awards, Synack has put the trust and privacy of its customers first. LaunchPoint+ is another example of that commitment.

For Synack customers, the company’s new workspace will enable endpoint control, data privacy objectives, and improved trust between customers and researchers.

“We’ve set out to build trust between organizations and ethical hackers since our founding in 2013. We’re really excited to continue enhancing the Synack platform with technology feature updates like LaunchPoint+, because these are what give customers more control and make the crowdsourced testing model more trusted,” Synack CTO and co-founder Mark Kuhr said.

“The ability to have enhanced security controls directly applied to the attack workstation will help ensure data privacy and compliance requirements are met and consistently enforced,” says David Charlton, former Head of Penetration Testing at J.P. Morgan Chase & Co, and Synack’s Head of Product Strategy.

For Synack Red Team researchers, LaunchPoint+ will eradicate the need to manually connect to a VPN server and ensure a stable connection with reduced network latency. When asked for feedback, Synack Red Team researchers said they were “happy with the concept”, “a fan of the increased bandwidth”, and could “definitely see myself using this a lot.”

As more security teams move towards crowdsourced penetration testing, Synack leads the way in trust by offering features like LaunchPoint+ that ensure private, safe and controlled testing.

About Synack

Synack, the most trusted crowdsourced security company, delivers comprehensive and continuous penetration testing with actionable results. The company combines the world's most skilled and trusted ethical hackers with AI-enabled technology to create a scalable, effective security solution. Headquartered in Silicon Valley with regional offices around the world, Synack protects leading global banks, federal agencies, DoD classified assets, and close to $1 trillion in Fortune 500 revenue. Synack was founded in 2013 by former US Department of Defense hackers Jay Kaplan, CEO, and Dr. Mark Kuhr, CTO. For more information, please visit www.synack.com .

Contact:

Ellie McCardwell press@synack.com

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye